compname reports earnings for q2, q2 of 2021; provides additional guidance and provides outlook for 2020.
q2 adjusted earnings per share $1.00.
qtrly reported revenue rose 1 percent to $1.3 billion, while reported sales increased 2 percent to second quarter of fiscal 2020.
q1 revenue up 8%.
q3 results include growth in international businesses and an organic decrease in non-gaap sales.
q3 adjusted earnings per share $0.63.
compname reports third quarter 2020 diluted earnings per share $0.57.
reiterating operating guidance for 2021 and 2020 business performance as of october 1.
reasons for guidance is not provided at this time.
paraphrase, excluding impact of foreign exchange, does not include impact of u.s. currency effects.
paraphrase - expect to see continued strong results of capital expenditures in 2020, including continued improvements in production levels related to cyclophosphamide.
compname reports q3 sales $1.6 billion versus refinitiv ibes estimate of $1 billion.
qtrly non-gaap sales of $607 million increased 6% compared with $587 million in q4 2021.
q3 sales rose 27 percent to $1.21 billion.
qtrly global sales rose 4 percent to $568 million.
qtrly u.s. sales of about $1 billion.
